Current stage-Stage IV Posts on Medivizor
Navigation Menu

Current stage-Stage IV Posts on Medivizor

Comparing the effectiveness and safety of chemotherapy-based combination therapies as first-line treatment for advanced non-small cell lung cancer with negative PD-L1.

Comparing the effectiveness and safety of chemotherapy-based combination therapies as first-line treatment for advanced non-small cell lung cancer with negative PD-L1.

Posted by on Oct 22, 2023 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of chemotherapy-based combination therapies for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with negative PD-L1 expression. The data showed that pembrolizumab (Keytruda) plus chemotherapy combination was the best treatment regimen for improving overall survival...

Read More

How useful is thoracic tumor radiation in improving overall survival of patients with non-small-cell lung cancer and malignant pleural effusion?

How useful is thoracic tumor radiation in improving overall survival of patients with non-small-cell lung cancer and malignant pleural effusion?

Posted by on Sep 17, 2023 in Lung cancer | 0 comments

In a nutshell This study investigated the effect of thoracic tumor radiotherapy on overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) with malignant pleural effusion (MPE). The authors concluded that thoracic tumor radiotherapy effectively improved OS with acceptable toxicity levels in these patients. Some background...

Read More

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Posted by on Aug 27, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of panitumumab (Vectibix) rechallenge when added to maintenance therapy with FOLFIRI {fluorouracil (FU; Adrucil), folinic acid (FA; Leucovorin), irinotecan (Camptosar)} in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with...

Read More

Comparing the long-term effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Comparing the long-term effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Posted by on Jun 11, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of trastuzumab deruxtecan (TD; Enhertu) with trastuzumab emtansine (TE; Kadcyla) in patients with HER2-positive (HER2+) metastatic breast cancer (BC). The study found that TD was more effective and well-tolerated compared to TE in these patients. Some background HER2+ BC...

Read More

Evaluating the effectiveness of chemotherapy for patients with resectable colorectal cancer liver metastases.

Evaluating the effectiveness of chemotherapy for patients with resectable colorectal cancer liver metastases.

Posted by on Jun 11, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy before surgery for the treatment of patients with resectable colorectal cancer liver metastasis (CRLM). The data showed that the addition of chemotherapy before surgery significantly improved disease-free survival (survival without any signs or symptoms of cancer) but not the...

Read More

Evaluating the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple negative breast cancer.

Evaluating the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple negative breast cancer.

Posted by on May 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple-negative breast cancer (TNBC). This study concluded that the combination of taxanes and chemotherapy is effective with manageable side effects in these patients. Some background TNBC is a subtype of BC that tests...

Read More

Evaluating the safety and effectiveness of nivolumab and relatlimab before surgery in patients with resectable melanoma

Evaluating the safety and effectiveness of nivolumab and relatlimab before surgery in patients with resectable melanoma

Posted by on Apr 15, 2023 in Melanoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of relatlimab (Opdualag) and nivolumab (Opdivo) combination therapy before surgery in patients with stages III and IV resectable melanoma. The study concluded that the relatlimab and nivolumab combination was safe and effective in these patients. Some background...

Read More

Which sequence of treatment should be given first- immunotherapy or targeted therapy for patients with BRAF-mutated metastatic melanoma?

Which sequence of treatment should be given first- immunotherapy or targeted therapy for patients with BRAF-mutated metastatic melanoma?

Posted by on Mar 26, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated which sequence of treatment should be given first – immunotherapy or targeted therapy – for the most clinical benefit in patients with BRAF-mutated metastatic melanoma. The data showed that immunotherapy followed by targeted therapy significantly improved survival outcomes in these patients. Some background...

Read More

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Posted by on Mar 5, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) for the treatment of patients with colorectal cancer liver metastasis (CRLM) at high risk. The data showed that NAC improved the overall survival of these patients. Some background Colorectal cancer (CRC) is one of the most common...

Read More

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Posted by on Mar 5, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) either alone or in combination for the treatment of patients with advanced melanoma. The data showed that nivolumab (Opdivo) and ipilimumab (Yervoy) combination therapy was more effective than nivolumab or ipilimumab alone for the treatment of...

Read More

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Posted by on Jan 8, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving...

Read More

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Posted by on Dec 31, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of anlotinib (AL3818) as a third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that anlotinib as a third-line treatment was effective with manageable side effects in these patients. Some background NSCLC is the most common form of lung...

Read More